Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial

被引:83
作者
Apostolakis, Stavros [1 ]
Lane, Deirdre A. [1 ]
Buller, Harry [2 ]
Lip, Gregory Y. H. [1 ]
机构
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
[2] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
关键词
Atrial fibrillation; bleeding risk; oral anticoagulation; HAS-BLED; CHADS(2); CHA(2)DS(2)-VASc; RISK; WARFARIN; HEMORRHAGE; OUTCOMES; THERAPY;
D O I
10.1160/TH13-07-0552
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many of the risk factors for stroke in atrial fibrillation (AF) are also important risk factors for bleeding. We tested the hypothesis that the CHADS(2) and CHA(2)DS(2)-VASc scores (used for stroke risk assessment) could be used to predict serious bleeding, and that these scores would compare well against the HAS-BLED score, which is a specific risk score designed for bleeding risk assessment. From the AMADEUS trial, we focused on the trial's primary safety outcome for serious bleeding, which was "any clinically relevant bleeding". The predictive value of HAS-BLED/CHADS(2)/CHA(2)DS(2)-VASc were compared by area under the curve (AUC, a measure of the c-index) and the Net Reclassification Improvement (NRI). Of 2,293 patients on VKA, 251 (11%) experienced at least one episode of "any clinically relevant bleeding" during an average 429 days follow up period. Incidence of "any clinically relevant bleeding" rose with increasing HAS-BLED/CHADS(2)/CHA(2)DS(2)-VASc scores, but was statistically significant only for HAS-BLED (p<0.0001). Only HAS-BLED demonstrated significant discriminatory performance for "any clinically relevant bleeding" (AUC 0.60, p<0.0001). There were significant AUC-differences between HAS-BLED (which had the highest AUC) and both CHADS(2) (p<0.001) and CHA(2)DS(2)VASc (p=0.001). The HAS-BLED score also demonstrated significant NRI for the outcome of "any clinically relevant bleeding" when compared with CHADS(2) (p=0.001) and CHA(2)DS(2)-VASc (p=0.04). In conclusion, the HAS-BLED score demonstrated significant discriminatory performance for "any clinically relevant bleeding" in anticoagulated patients with AF, whilst the CHADS(2) and CHA(2)DS(2)-VASc scores did not. Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS(2) or CHA(2)DS(2)-VASc scores should not be used.
引用
收藏
页码:1074 / 1079
页数:6
相关论文
共 23 条
[1]  
[Anonymous], PRAD PRESCR INF
[2]   Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation [J].
Apostolakis, Stavros ;
Lane, Deirdre A. ;
Guo, Yutao ;
Buller, Harry ;
Lip, Gregory Y. H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (09) :861-867
[3]  
Bousser MG, 2008, LANCET, V371, P315, DOI 10.1016/S0140-6736(08)60168-3
[4]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[5]   Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation A Report From the Swedish Atrial Fibrillation Cohort Study [J].
Friberg, Leif ;
Rosenqvist, Marten ;
Lip, Gregory Y. H. .
CIRCULATION, 2012, 125 (19) :2298-+
[6]   Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation [J].
Gallego, Pilar ;
Roldan, Vanessa ;
Miguel Torregrosa, Jose ;
Galvez, Josefa ;
Valdes, Mariano ;
Vicente, Vicente ;
Marin, Francisco ;
Lip, Gregory Y. H. .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2012, 5 (02) :312-318
[7]   Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey [J].
Holt, Tim A. ;
Hunter, Tina D. ;
Gunnarsson, Candace ;
Khan, Nada ;
Cload, Paul ;
Lip, Gregory Y. H. .
BRITISH JOURNAL OF GENERAL PRACTICE, 2012, 62 (603) :e710-e717
[8]   Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation [J].
Hylek, Elaine M. ;
Evans-Molina, Carmella ;
Shea, Carol ;
Henault, Lori E. ;
Regan, Susan .
CIRCULATION, 2007, 115 (21) :2689-2696
[9]   Assessing the Risk of Bleeding in Patients With Atrial Fibrillation The Loire Valley Atrial Fibrillation Project [J].
Lip, Gregory Y. H. ;
Banerjee, Amitava ;
Lagrenade, Isabelle ;
Lane, Deirdre A. ;
Taillandier, Sophie ;
Fauchier, Laurent .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2012, 5 (05) :941-948
[10]   Bleeding risk assessment and management in atrial fibrillation patients Executive Summary* of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis [J].
Lip, Gregory Y. H. ;
Andreotti, Felicita ;
Fauchier, Laurent ;
Huber, Kurt ;
Hylek, Elaine ;
Knight, Eve ;
Lane, Deirdre ;
Levi, Marcel ;
Marin, Francisco ;
Palareti, Gualtiero ;
Kirchhof, Paulus .
THROMBOSIS AND HAEMOSTASIS, 2011, 106 (06) :997-1011